evidence: Anyone receiving any COVID-19 vaccine should be informed of the risks associated with COVID-19 vaccines (myocarditis/pericarditis and anaphylaxis) and be advised to seek medical attention if they develop signs or symptoms suggestive of these conditions. [...] Evidence from bivalent and original mRNA COVID-19 vaccines across different age groups show that the risk of myocarditis is lower following boosters compared to dose 2 of the primary series, and that no product-specific difference in the risk of myocarditis has been identified following a booster dose at this time, including in adolescents 12 to 17 years of age. However, the use of Moderna Spikevax COVID-19 vaccines had been limited in those 5 to 17 years of age. While long-term follow-up is ongoing, available data indicate that the majority of individuals who reported myocarditis/pericarditis after mRNA COVID-19 vaccination, though requiring hospitalization, have responded well to conservative therapy and tend to recover quickly. [...] Selected references - Abraham N, Spruin S, Rossi T, Fireman B, Zafack J, Blaser C, et al. Myocarditis and/or Pericarditis Risk After mRNA COVID-19 Vaccination: A Canadian Head to Head Comparison of BNT162b2 and mRNA-1273 Vaccines. JVAC-D-21-03106, Available at SSRN: https://ssrn.com/abstract=3988612 - AstraZeneca Canada Inc. Product monograph - Evusheld™. April 14, 2022.